Cost-effectiveness of beta-blocker treatment in heart failure.
There is a growing economic burden from the treatment of heart failure that accounts for more than 5% of total health care expenditures. Hospitalization contributes between 60% and 75% of this total expense. The addition of beta-blockers to conventional heart failure therapy results in a significant reduction in hospitalization. As a consequence, beta-blocker therapy in heart failure is very cost-effective and compares favorably to that of other generally accepted medical interventions
Gilbert
Edward M
EM
Division of Cardiology, University of Utah School of Medicine, Salt Lake City, Utah, USA.
D000319:Adrenergic beta-Antagonists / Q000191:economics* / Q000627:therapeutic use*; D001315:Australia; D002227:Carbazoles / Q000191:economics / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D003362:Cost-Benefit Analysis; D003695:Delivery of Health Care / Q000191:economics; D005060:Europe; D006333:Heart Failure / Q000188:drug therapy* / Q000191:economics*; D006760:Hospitalization / Q000191:economics; D006801:Humans; D009520:New Zealand; D010043:Outcome and Process Assessment, Health Care; D014481:United States
D000319:Adrenergic beta-Antagonists; D002227:Carbazoles